The review found no eligible studies for this question.
Intravenous showed no clear difference in adverse events: leucopenia compared with oral cyclophosphamide (low certainty).
Intravenous showed no clear difference in adverse events: hair loss compared with oral cyclophosphamide (low certainty).
Intravenous may leads to lower adverse events: all infections compared with oral cyclophosphamide (low certainty).
It is very uncertain whether intravenous changes adverse events: nausea and vomiting compared with oral cyclophosphamide (very low certainty).
IV showed no clear difference in complete remission compared with oral cyclophosphamide (low certainty).
IV showed no clear difference in partial remission compared with oral cyclophosphamide (low certainty).
IV showed no clear difference in continuing remission at one year compared with oral cyclophosphamide (low certainty).
IV showed no clear difference in adverse events: renal insufficiency compared with oral cyclophosphamide (low certainty).
It is very uncertain whether IV changes adverse events: bacterial infection compared with oral cyclophosphamide (very low certainty).
It is very uncertain whether IV changes adverse events: vomiting compared with oral cyclophosphamide (very low certainty).
IV showed no clear difference in adverse events: alopecia compared with oral cyclophosphamide (low certainty).